BRKR
Bruker Corporation
NASDAQ · USHealthcareMedical - Devices
$56.17-3.54%
Price as of Jul 20, 2026
BRKR financials
Bruker Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $3.4B | $3.4B | $3.0B | $2.5B |
| Cost of revenue | $1.9B | $1.7B | $1.5B | $1.2B |
| Gross profit | $1.6B | $1.6B | $1.5B | $1.3B |
| Operating expenses | $1.3B | $1.4B | $1.1B | $873.0M |
| Operating income | $236.0M | $253.1M | $436.9M | $432.7M |
| Net income | -$8.6M | $113.1M | $427.2M | $296.6M |
| EBITDA | $302.6M | $438.6M | $675.5M | $518.7M |
| Basic EPS | $-0.15 | $0.76 | $2.92 | $2.00 |
| Diluted EPS | $-0.15 | $0.76 | $2.90 | $1.99 |
| Balance sheet | ||||
| Cash & equivalents | $298.8M | $183.4M | $488.3M | $645.5M |
| Total assets | $6.2B | $5.8B | $4.2B | $3.6B |
| Total liabilities | $3.7B | $4.0B | $2.8B | $2.5B |
| Stockholders’ equity | $2.5B | $1.8B | $1.4B | $1.1B |
| Total debt | $2.0B | $2.2B | $1.4B | $1.3B |
| Net debt | $1.7B | $2.1B | $891.3M | $624.9M |
| Cash flow | ||||
| Operating cash flow | $134.1M | $251.3M | $350.1M | $274.4M |
| Capital expenditure | -$120.2M | -$115.3M | -$106.9M | -$129.2M |
| Free cash flow | $13.9M | $136.0M | $243.2M | $145.2M |
| Dividends paid | -$22.8M | -$30.2M | -$29.4M | -$29.8M |
| Share repurchases | -$10.0M | $0.00 | -$152.3M | -$263.1M |